Finding out that the medication you’ve been taking every morning—the one on your kitchen counter next to your coffee—might not have been working is unsettling. Patients who were prescribed a particular batch of the popular blood pressure drug chlorthalidone are currently in this predicament after a voluntary recall was discreetly started on June 5.
11,460 bottles of Chlorthalidone Tablets USP, 25 mg, produced by Mumbai-based Inventia Healthcare Limited and supplied nationwide by East Brunswick, New Jersey-based Rising Pharma Holdings, are included in the recall. The 100-tablet and 1,000-tablet sizes of the impacted bottles have an April 2027 expiration date, indicating that these are not outdated, expired drugs. They were probably active, up-to-date inventory that was kept in medicine cabinets and pharmacies.
The recall is due to what authorities refer to as “failed dissolution specifications.” To put it simply, during testing, the tablets failed to degrade as expected. When a pill dissolves improperly in the body, the active ingredient may not be released as intended, making the medication less effective. This is not a minor annoyance for someone who is managing hypertension, a condition that can silently cause major harm to the heart, kidneys, and brain if left untreated.
Chlorthalidone is a member of the class of medications known as diuretics, or “water pills.” It lowers blood pressure by encouraging the kidneys to eliminate extra fluid and salt. Additionally, it is used to treat fluid retention brought on by liver, kidney, or heart conditions. It is not something that many patients take on a sporadic basis. Since it’s a daily medication, abruptly stopping it could be dangerous.
It’s worth taking a moment to consider that final point. The first thing that comes to mind when you hear “recall” is to immediately stop taking the medication. However, medical professionals have consistently advised against doing so without first consulting a physician. The risk of stopping a blood pressure medication suddenly can sometimes be greater than the risk of the recall itself, according to Jennifer Young, a clinical pharmacist and lead medication safety specialist at the Institute for Safe Medication Practices. The noise of a recall announcement obscures this counterintuitive notion.
Customers do not yet have a clear government-issued directive on what to do because the FDA has not yet given this recall a formal risk classification. For patients who take this medication on a daily basis and are understandably anxious, that lack of guidance can be somewhat frustrating. As its evaluation progresses, it is still unclear if the agency will elevate the classification or provide more detailed consumer instructions.
Patients can currently check if their bottles match the impacted batch codes (RISB24002 for the 1,000-tablet bottles and RISA24001 for the 100-tablet size) and contact their doctor or pharmacist before making any changes. In any case, the discussion is worthwhile. Your doctor might want to switch you to a different lot or an alternate medication in the interim if your prescription matches the recalled lot.
Over the past few years, recalls involving imported pharmaceuticals have come under increasing scrutiny. This situation fits into a larger, ongoing discussion about manufacturing standards for medications made outside of the United States. It’s unclear at this point whether this specific instance is an isolated quality control failure or a systemic problem. However, it’s the kind of story that, particularly for the patients at the center of it, tends to linger longer than the initial headlines suggest.
